IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of ...

into a Phase 1 study in the U.S. DLL3 is upregulated in multiple solid tumor types, including small cell lung cancer (SCLC), neuroendocrine tumors (NETs), non-small cell lung cancer (NSCLC ...

IDE849 (SHR-4849): a potential first-in-class Phase 1 DLL3 TOP1i antibody drug conjugate (ADC) targeting small cell lung cancer (SCLC) and neuroendocrine ... driven anti-tumor immunity was ...

March 31, 2025, and an updated cash runway guidance into 2029; commercial readiness activities ongoing Over 300 patients enrolled in darovasertib and crizotinib registrational 1L HLA-A2-negative MUM ...

M: Metastasis; N: Node; T: Tumor. Data from [21]. Neuroendocrine tumors have demonstrated an increase in incidence and prevalence over the past decades, partly due to increased awareness ...

The appointments also give you the chance to raise any concerns you have about your progress. the grade of your neuroendocrine cancer the type of neuroendocrine cancer whether it has spread to other ...

The most common symptoms are coughing, shortness of breath and chest pains. Co-occurring mutations in the tumor suppressor LKB1 are frequent in KRAS-mutant lung cancers. Here, the authors show ...

The FDA previously designated the ADC as a breakthrough drug for relapsed or refractory extensive-stage small-cell lung cancer (SCLC), with the EMA awarding Priority Medicine (PRIME) status to the ...

7) Amgen's Imdelltra/Imdylltra (tarlatamab), DLL3×CD3-targeting bispecific T-cell engager (BiTE) for extensive stage small cell lung cancer (ES-SCLC), the first DLL3-directed therapy to reach the ...

Martín-Arana et al. present a highly sensitive tumor-agnostic assay to detect minimal residual disease based on whole-exome sequencing of longitudinal circulating tumor DNA samples from persons ...